Journal: Oncotarget

Article Title: Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation

doi: 10.18632/oncotarget.18749

Figure Lengend Snippet: (A) Western blot analysis of protein expression in GEO, SW48, GEO-CR and SW48-CR cells treated with cetuximab (5 μg/ml) and SYM004 (5 μg/ml) was performed. Total cell protein extracts were subjected to immuneblotting with the indicated antibodies, as described in Materials and Methods. (B) Two mg of GEO cell or of GEO-CR cell protein extracts were immune-precipitated with a specific anti-MET antibody and then were immune-blotted with a specific anti-EGFR antibody, as described in Materials and Methods. (C) Western blot analysis of protein expression in SW48, SW48-CR, SW48H2 and SKBR3 was performed. Total cell protein extracts were subjected to immuneblotting with the indicated antibodies, as described in Materials and Methods. (D) HER2 gene amplified SW48 cells line (SW48H2) are exposed to different concentration of cetuximab (range, 0.001 to 10 μg/ml) and SYM004 (range, 0.001 to 10 μg/ml) for 96 hours and evaluated for proliferation by MTT staining, as described in Materials and Methods.

Article Snippet: The human SW48 (catalogue number: HTL99020) ( KRAS, NRAS, BRAF and PIK3CA WT), colon cancer cell line was obtained from IRCCS “Azienda Ospedaliera Universitaria San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genova” Italy.

Techniques: Western Blot, Expressing, Amplification, Concentration Assay, Staining

Journal: Oncotarget

Article Title: Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation

doi: 10.18632/oncotarget.18749

Figure Lengend Snippet: (A-B) Mice were injected subcutaneously in the right flank with SW48 cells as described in the Materials and Methods. After two weeks (average tumor size 200-300 mm 3 ) mice were treated intraperitoneally with: PBS control, cetuximab (1 mg twice a week), SYM004 (50 mg/kg twice a week). The treatment was continued for 30 weeks. Each group consisted of 10 mice. Tumor volumes were measured three times a week. Animals were sacrificed when tumors achieved 2.000 mm 3 in size. Abbreviations: CTR, control; A, median tumor volume (mm 3 ); B, alive mice/total mice; C, number of mice without clinical evidence of progression.

Article Snippet: The human SW48 (catalogue number: HTL99020) ( KRAS, NRAS, BRAF and PIK3CA WT), colon cancer cell line was obtained from IRCCS “Azienda Ospedaliera Universitaria San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genova” Italy.

Techniques: Injection, Control

Journal: Oncotarget

Article Title: Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation

doi: 10.18632/oncotarget.18749

Figure Lengend Snippet: (A-B) SW48 cells were injected s.c. into the right flank of seven nude mice. After two weeks mice were treated with Cetuximab (1 mg twice a week) by i.p. injection. Treatment was continued until disease progression. The black arrows indicate the time of progression to cetuximab. At progression phase mice were assigned to SYM004 treatment (50 mg/Kg twice a week) by i.p. injection. The treatment was continued until 30 weeks. At week 30 four out of seven mice were still responding to SYM004 (as indicated by double asterisk). Abbreviations: PD, progression disease; PR, partial response; SD, stable disease.

Article Snippet: The human SW48 (catalogue number: HTL99020) ( KRAS, NRAS, BRAF and PIK3CA WT), colon cancer cell line was obtained from IRCCS “Azienda Ospedaliera Universitaria San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genova” Italy.

Techniques: Injection, Biomarker Discovery